Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6242209 | Respiratory Medicine | 2011 | 12 Pages |
Abstract
Early stage COPD carries a significant healthcare burden that is currently underrecognised, underdiagnosed and undertreated. Furthermore, patients at this stage can rapidly decline to advanced disease, especially if they continue to smoke. The natural history of the disease in early stages remains largely unknown, and emerging evidence indicates that we are able to reduce lung function decline and exacerbations, and improve quality of life, in early stage COPD, mainly through smoking cessation. But new evidence from randomised clinical trials also suggests an impact of pharmacotherapy on clinical outcomes in early disease. Guidelines need to be updated to reflect this greater understanding of early stage disease, and trials need to be conducted to definitively show the benefits of intensive treatment so that we can meet the large, unmet clinical needs of this important patient group.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Marc Decramer, Marc Miravitlles, David Price, Miguel Román-RodrÃguez, Carl Llor, Tobias Welte, Roland Buhl, Daniel Dusser, Katerina Samara, Nikolaus Siafakas,